Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
VBI Vaccines
VBI Vaccines
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
VBI Vaccines receives positive EMA Scientific Advice regarding Sci-B-Vac Phase III clinical Study
VBI Vaccines Inc. has received positive Scientific Advice for its Sci-B-Vac vaccine in Europe
Research & Development
VBI Vaccines appoints Dr Francisco Diaz-Mitoma as Chief Medical Officer
He will oversee clinical development initiatives at the firm
Research & Development
VBI Vaccines applies its eVLP platform to development of Zika vaccine
The eVLP platform enables the development of vaccines that mimic the structure of viruses found in nature
Research & Development
Sanofi Pasteur to use VBI technology to develop more stable vaccine candidate
French company has the option to acquire certain worldwide rights to LPV technology
Subscribe now